News

The trail is the first to use the company’s commercial room-temperature-stable formulation and provide confirmatory proof-of-concept for the final stage of development of its cat allergy T-cell vaccine.

Under the agreement, NU100 will be generated at Catalent’s facility in Brussels, Belgium, where the injectable product will be formulated, filled and packaged in a prefilled syringe. Nuron

The product will be launched starting in February 2011 through its subsidiary Nutrition & Sante SAS (N&S). Soyjoy, a fruit soy bar made from soy flour, is based

The study will assess the benefits of Sideguard stent as primary intervention, for managing bifurcation related coronary artery disease. The Sideguard stent is designed to preserve the sidebranch

Emphusion targets development programs in biotechnology, medical device, and pharmaceutical industries when these services are a key to success. "Through acquisition and internal initiatives, we have grown our

The study updates research that showed a link between the therapy– known as HRT– and breast cancer risk, and is the first to investigate the timing of the

Greystone managing director George Perros said that the chronic nature of diseases and conditions in these segments makes repetitive dosing necessary and thus the availability of therapies in

The tie up is expected to accelerate the development of ImaginAb’s pipeline of targeted molecular imaging agents for the diagnosis and treatment management of cancer and autoimmune diseases.

The company’s decision follows positive results from Phase 1/2 clinical study of AST-915 which showed that the drug is safe and well tolerated and demonstrated a clear effect